Menin inhibitors (revumenib, ziftomenib, enzomenib, bleximenib) achieve ORRs of 33-88% in KMT2A-rearranged or <i>NPM1</i>-mutated AML, with DS in 10-25% and QT prolongation as key toxicities. The gene discussed is MEN1; the disease is acute myeloid leukemia.